Technical Analysis for OCGN - Ocugen, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 4.84% | |
| Crossed Above 50 DMA | Bullish | 4.84% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 4.84% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 5 hours ago |
| Expansion Pivot Buy Entry | about 5 hours ago |
| Rose Above Previous Day's High | about 5 hours ago |
| Up 5% | about 5 hours ago |
| Up 3% | about 5 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/21/2024
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Eye Ophthalmology Vision Diabetic Retinopathy Eye Diseases Retina Blindness Retinopathy Host Disease Innovative Therapies Retinitis Graft Versus Host Disease Retinitis Pigmentosa
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Eye Ophthalmology Vision Diabetic Retinopathy Eye Diseases Retina Blindness Retinopathy Host Disease Innovative Therapies Retinitis Graft Versus Host Disease Retinitis Pigmentosa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.105 |
| 52 Week Low | 0.345 |
| Average Volume | 6,917,619 |
| 200-Day Moving Average | 0.90 |
| 50-Day Moving Average | 1.55 |
| 20-Day Moving Average | 1.49 |
| 10-Day Moving Average | 1.37 |
| Average True Range | 0.14 |
| RSI (14) | 56.14 |
| ADX | 20.35 |
| +DI | 23.54 |
| -DI | 20.38 |
| Chandelier Exit (Long, 3 ATRs) | 1.42 |
| Chandelier Exit (Short, 3 ATRs) | 1.58 |
| Upper Bollinger Bands | 1.85 |
| Lower Bollinger Band | 1.13 |
| Percent B (%b) | 0.69 |
| BandWidth | 47.95 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.0173 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.85 | ||||
| Resistance 3 (R3) | 1.83 | 1.74 | 1.81 | ||
| Resistance 2 (R2) | 1.74 | 1.68 | 1.75 | 1.80 | |
| Resistance 1 (R1) | 1.68 | 1.64 | 1.71 | 1.70 | 1.79 |
| Pivot Point | 1.59 | 1.59 | 1.60 | 1.60 | 1.59 |
| Support 1 (S1) | 1.53 | 1.53 | 1.56 | 1.55 | 1.46 |
| Support 2 (S2) | 1.44 | 1.49 | 1.45 | 1.45 | |
| Support 3 (S3) | 1.38 | 1.44 | 1.44 | ||
| Support 4 (S4) | 1.40 |
